Biological and physico-chemical characterization of human norovirus-like particles under various environmental conditions.

Aggregate HBGA Ligand affinity Norovirus Stability VLP

Journal

Colloids and surfaces. B, Biointerfaces
ISSN: 1873-4367
Titre abrégé: Colloids Surf B Biointerfaces
Pays: Netherlands
ID NLM: 9315133

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 27 07 2023
revised: 07 09 2023
accepted: 12 09 2023
medline: 3 11 2023
pubmed: 24 9 2023
entrez: 23 9 2023
Statut: ppublish

Résumé

Human noroviruses (HuNoVs) are the predominant etiological agent of viral gastroenteritis in all age groups worldwide. Mutations over the years have affected noroviruses' responses to environmental conditions due to the arrangement of amino acid residues exposed on the VP1 capsid surface of each strain. The GII.4 HuNoV genotype has been the predominant variant for decades, while the GII.17 genotype has often been detected in East Asia since 2014. Here, GII.17 and GII.4 baculovirus-expressed VLPs (virus-like particles) were used to study the biological (binding to HuNoV ligand, namely the ABO and Lewis antigens) and physicochemical properties (size, morphology, and charge) of the HuNoV capsid under different conditions (temperature, pH, and ionic strength). GII.17 showed stability at low and high ionic strength, while GII.4 aggregated at an ionic strength of 10 mM. The nature of the buffers influences the morphology and stability of the VLPs. Here, both VLPs were highly stable from pH 7-8.5 at 25 °C. VLPs retained HBGA binding capability for the pH, ionic strength and temperature encountered in the stomach (fed state) and the small intestine. Increasing the temperature to above 65 °C altered the morphology of VLPs, causing aggregation, and decreased their affinity to HBGAs. Comparing both isolates, GII.17 showed a better stability profile and higher affinity to HBGAs than GII.4, making them interesting candidate particles for a future norovirus vaccine. Biological and physicochemical studies of VLPs are as pertinent as ever in view of the future arrival of VLP-based HuNoV vaccines.

Identifiants

pubmed: 37741147
pii: S0927-7765(23)00423-X
doi: 10.1016/j.colsurfb.2023.113545
pii:
doi:

Substances chimiques

Capsid Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113545

Informations de copyright

Copyright © 2023. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Nicole Abou-Hamad (N)

National Reference Centre for Viral Gastroenteritis, Laboratory of Virology, University Hospital of Dijon, France; UMR PAM A 02.102, UBFC / Institut Agro Dijon, France; Laboratoire ICB UMR 6303 CNRS/Université de Bourgogne, 9 av. Alain Savary, BP 47870, 21078 Dijon Cedex, France.

Marie Estienney (M)

National Reference Centre for Viral Gastroenteritis, Laboratory of Virology, University Hospital of Dijon, France; UMR PAM A 02.102, UBFC / Institut Agro Dijon, France.

Rémi Chassagnon (R)

Laboratoire ICB UMR 6303 CNRS/Université de Bourgogne, 9 av. Alain Savary, BP 47870, 21078 Dijon Cedex, France.

Marjorie Bon (M)

National Reference Centre for Viral Gastroenteritis, Laboratory of Virology, University Hospital of Dijon, France.

Philippe Daval-Frerot (P)

National Reference Centre for Viral Gastroenteritis, Laboratory of Virology, University Hospital of Dijon, France.

Alexis de Rougemont (A)

National Reference Centre for Viral Gastroenteritis, Laboratory of Virology, University Hospital of Dijon, France; UMR PAM A 02.102, UBFC / Institut Agro Dijon, France.

Stéphane Guyot (S)

UMR PAM A 02.102, UBFC / Institut Agro Dijon, France.

Frédéric Bouyer (F)

Laboratoire ICB UMR 6303 CNRS/Université de Bourgogne, 9 av. Alain Savary, BP 47870, 21078 Dijon Cedex, France. Electronic address: frederic.bouyer@u-bourgogne.fr.

Gaël Belliot (G)

National Reference Centre for Viral Gastroenteritis, Laboratory of Virology, University Hospital of Dijon, France; UMR PAM A 02.102, UBFC / Institut Agro Dijon, France. Electronic address: gael.belliot@u-bourgogne.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH